CO5640147A2 - Metodos y composiciones para inducir apoptosis de cedulas cancerosas - Google Patents

Metodos y composiciones para inducir apoptosis de cedulas cancerosas

Info

Publication number
CO5640147A2
CO5640147A2 CO05062795A CO05062795A CO5640147A2 CO 5640147 A2 CO5640147 A2 CO 5640147A2 CO 05062795 A CO05062795 A CO 05062795A CO 05062795 A CO05062795 A CO 05062795A CO 5640147 A2 CO5640147 A2 CO 5640147A2
Authority
CO
Colombia
Prior art keywords
apoptosis
canoper
ced
induce
compositions
Prior art date
Application number
CO05062795A
Other languages
English (en)
Inventor
Marc Nasoff
Quinn L Deveraux
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of CO5640147A2 publication Critical patent/CO5640147A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/207—Modifications characterised by siRNA, miRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

1.- Un método para inducir apoptosis en una célula cancerosa, el método comprende poner en contacto la célula con:i. un agente agonista de afinidad anti-DR4 o anti-DR5; y ii. un agente que induce la apoptosis.
CO05062795A 2002-11-27 2005-06-27 Metodos y composiciones para inducir apoptosis de cedulas cancerosas CO5640147A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42984202P 2002-11-27 2002-11-27
US44896003P 2003-02-21 2003-02-21
US49471403P 2003-08-12 2003-08-12
US50490103P 2003-09-22 2003-09-22

Publications (1)

Publication Number Publication Date
CO5640147A2 true CO5640147A2 (es) 2006-05-31

Family

ID=32475709

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05062795A CO5640147A2 (es) 2002-11-27 2005-06-27 Metodos y composiciones para inducir apoptosis de cedulas cancerosas

Country Status (17)

Country Link
US (2) US7229617B2 (es)
EP (1) EP1576179B1 (es)
JP (1) JP2006514096A (es)
KR (3) KR100915257B1 (es)
AT (1) ATE481092T1 (es)
AU (1) AU2003297579A1 (es)
BR (1) BR0316737A (es)
CA (1) CA2507077A1 (es)
CO (1) CO5640147A2 (es)
DE (1) DE60334247D1 (es)
EC (1) ECSP055818A (es)
MX (1) MXPA05005726A (es)
NO (1) NO20052922L (es)
PL (1) PL210174B1 (es)
PT (1) PT1576179E (es)
RU (1) RU2379056C2 (es)
WO (1) WO2004050895A2 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030180296A1 (en) * 2001-12-20 2003-09-25 Theodora Salcedo Antibodies that immunospecifically bind to trail receptors
US7229617B2 (en) * 2002-11-27 2007-06-12 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
CN1980957A (zh) * 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
EP1824498A4 (en) * 2004-11-12 2009-06-24 Massachusetts Inst Technology METHODS AND COMPOSITIONS FOR TREATING CELLULAR PROLIFERATIVE DISEASES
US8440610B2 (en) 2004-11-12 2013-05-14 Massachusetts Institute Of Technology Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
JP2008536820A (ja) * 2005-03-24 2008-09-11 アイアールエム・リミテッド・ライアビリティ・カンパニー 癌のｄｒ５アゴニストに対するｍｙｃ依存性感受性の増強
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
WO2007094842A2 (en) * 2005-12-02 2007-08-23 Genentech, Inc. Binding polypeptides and uses thereof
WO2007025231A2 (en) * 2005-08-26 2007-03-01 The Trustees Of The University Of Pennsylvania Methods using snail transcriptional repressor
JP2009512719A (ja) * 2005-10-25 2009-03-26 アエゲラ セラピューティクス インコーポレイテッド Ｉａｐｂｉｒドメイン結合化合物
TWI504597B (zh) * 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
GB0606096D0 (en) 2006-03-27 2006-05-03 Cbmm Sa Screening method
US8163792B2 (en) 2006-05-16 2012-04-24 Pharmascience Inc. IAP BIR domain binding compounds
TWI389895B (zh) * 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
WO2008066854A2 (en) * 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
WO2008144925A1 (en) * 2007-05-30 2008-12-04 Aegera Therapeutics Inc. Iap bir domain binding compounds
WO2008154439A1 (en) * 2007-06-08 2008-12-18 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
US20100183604A1 (en) * 2007-06-19 2010-07-22 Takeda Pharmaceutical Company Limited Preventive/remedy for cancer
US20100272706A1 (en) 2007-06-22 2010-10-28 Jason Mercer Antivirals
EP2591804A3 (en) * 2007-09-24 2014-04-16 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
US20110117081A1 (en) * 2008-05-05 2011-05-19 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
EP2310402A1 (en) * 2008-06-27 2011-04-20 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
MX2011002759A (es) * 2008-09-22 2011-07-28 Amgen Inc Metodo de tratamiento.
JP2012512642A (ja) * 2008-12-18 2012-06-07 サントル・ナショナル・ドゥ・ラ・レシェルシュ・サイエンティフィーク−セ・エン・エール・エス− Ｔｒａｉｌ誘導アポトーシスに関する遺伝子の同定方法およびその治療適用
KR20120101050A (ko) 2009-11-05 2012-09-12 더 유에이비 리서치 파운데이션 기저형 유전자형 암의 치료 방법
US9238069B2 (en) 2009-12-16 2016-01-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
ES2625637T3 (es) 2010-02-12 2017-07-20 Pharmascience Inc. Compuestos de unión al dominio BIR IAP
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
CN105640964A (zh) 2010-04-21 2016-06-08 文蒂雷克斯药品公司 增强抗体依赖性细胞的细胞毒性的方法
AU2011321374B2 (en) 2010-10-29 2016-04-28 Daiichi Sankyo Company,Limited Novel anti-DR5 antibody
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
WO2012080260A1 (en) 2010-12-13 2012-06-21 Novartis Ag Dimeric iap inhibitors
US20140187604A1 (en) * 2011-05-03 2014-07-03 Dana-Farber Cancer Institute, Inc. Therapeutic and diagnostic target gene in acute myeloid leukemia
RU2488408C1 (ru) * 2012-03-22 2013-07-27 государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) Средство и способ индукции апоптоза опухолевых клеток
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US10689449B2 (en) 2015-01-20 2020-06-23 Igm Biosciences, Inc. Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
AU2015380455A1 (en) 2015-01-26 2017-08-03 Macrogenics, Inc. Multivalent molecules comprising DR5-binding domains
WO2017139485A1 (en) 2016-02-09 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment
CN109810193B (zh) * 2017-11-21 2020-11-03 深圳市中科艾深医药有限公司 抗dr5的抗体及其制备方法和应用
CN109810194B (zh) * 2017-11-21 2020-11-03 深圳市中科艾深医药有限公司 抗dr5的抗体及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DE69128362T2 (de) 1990-06-01 1998-05-20 Chiron Corp Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit
EP0758313A4 (en) 1994-05-06 1999-09-15 Pharmacopeia Inc COMBINATORIAL LIBRARY OF DIHYDROBENZOPYRANES
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
AUPQ599500A0 (en) 2000-03-02 2000-03-23 Walter And Eliza Hall Institute Of Medical Research, The Novel peptides, modulatory agents therefor and methods of using them
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
EP1315811A2 (en) 2000-08-24 2003-06-04 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
PL216750B1 (pl) * 2001-11-01 2014-05-30 Uab Research Foundation Zastosowanie przeciwciał selektywnych dla receptora liganda indukującego apoptozę pokrewnego czynnikowi martwicy nowotworu i innych czynników terapeutycznych do leczenia nowotworu oraz kompozycja zawierająca takie przeciwciała i inne czynniki terapeutyczne
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
US7229617B2 (en) 2002-11-27 2007-06-12 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
WO2005114187A2 (en) 2004-04-23 2005-12-01 The United States Of America As Represented By Thesecretary, Department Of Health And Human Services Methods and compositions for diagnosing aids and other diseases and conditions involving immune system activation
CA2571404A1 (en) 2004-06-21 2005-12-29 Washington University Antibodies against west nile virus and therapeutic and prophylactic uses thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .

Also Published As

Publication number Publication date
ATE481092T1 (de) 2010-10-15
DE60334247D1 (de) 2010-10-28
KR20090046973A (ko) 2009-05-11
KR100915257B1 (ko) 2009-09-03
MXPA05005726A (es) 2005-08-16
WO2004050895A3 (en) 2005-12-08
RU2379056C2 (ru) 2010-01-20
PT1576179E (pt) 2010-12-21
BR0316737A (pt) 2005-12-13
EP1576179A2 (en) 2005-09-21
WO2004050895A2 (en) 2004-06-17
AU2003297579A1 (en) 2004-06-23
PL210174B1 (pl) 2011-12-30
EP1576179B1 (en) 2010-09-15
KR20050094811A (ko) 2005-09-28
US8173128B2 (en) 2012-05-08
KR20070122578A (ko) 2007-12-31
CA2507077A1 (en) 2004-06-17
US20070128204A1 (en) 2007-06-07
EP1576179A4 (en) 2007-06-06
US20050079172A1 (en) 2005-04-14
NO20052922D0 (no) 2005-06-15
RU2005120167A (ru) 2006-03-10
US7229617B2 (en) 2007-06-12
NO20052922L (no) 2005-08-17
ECSP055818A (es) 2006-01-27
PL377726A1 (pl) 2006-02-06
JP2006514096A (ja) 2006-04-27

Similar Documents

Publication Publication Date Title
CO5640147A2 (es) Metodos y composiciones para inducir apoptosis de cedulas cancerosas
AR048819A1 (es) Metodos sinergicos y composiciones para el tratamiento del cancer
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
HN2005029978A (es) Formulaciones
MX2008016453A (es) Composiciones y metodos para tratar infecciones parasitas.
TW200501960A (en) Synergistic kits and compositions for treating cancer
AR060241A1 (es) Composiciones y metodos de uso para anticuerpos de c-met
CR11274A (es) Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
ECSP109940A (es) Anticuerpos anti-cd79b e inmunoconjugados humanizados y métodos de uso
BRPI0909227A2 (pt) uso de um anticorpo anti-cd20 tipo ii com aumentada citotoxicidade celular dependente de anticorpo (adcc) em combinação com ciclofosfamida, vincristina e doxorubicina para tratar linfomas não hodgkin.
UY30492A1 (es) Anticuerpo antagonista para el tratamiento del cancer
CL2008003122A1 (es) Uso de un anticuerpo anti-cd20 de tipo ii util para preparar un medicamento para tratar un cancer que expresa cd20 en combinacion con un inhibidor de proteasoma, composicion farmaceutica que contiene dicha combinacion y kit del mismo
EA200802285A1 (ru) Бивалентные миметики smac и их применения
CL2008002782A1 (es) Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
DK1915171T3 (da) Fremgangsmåde til bevarelse af funktionen af insulin-producerende celler
GT200900035A (es) Anticuerpo especifico prlr y sus usos
WO2006137934A3 (en) Purposeful movement of human migratory cells away from an agent source
BRPI0511396A (pt) derivados de retinal e métodos para uso no tratamento de enfermidades visuais
BRPI0606557A2 (pt) método de inibição do abrigo de her2, método de redução do nìvel em soro de domìnio extracelular (ecd) de her2 em mamìferos, métodos de tratamento de cáncer em mamìferos, método de redução do nìvel de p95 her2 em célula e método de diagnóstico
AU312968S (en) Plate
CR9853A (es) Compuestos de exemestano (s)-6-metiloxaalquilo y metodos relacionados con su utilizacion
HK1107778A1 (en) Sodium stibogluconate and il-2 for treating cancer
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
CR10201A (es) Metodos y composiciones para actuar sobre relt
AU316238S (en) Lawning applicator for microbiological cultures

Legal Events

Date Code Title Description
FC Application refused